Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 3/20 | 0.54 |
| ▸ | ESR1 | P03372 | 4/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19661678 | 0.83 | VHL (0.53) | VHLKDM4EPKMMEN1KMT2A | |
| SCHEMBL4048127 | 0.80 | VHL (0.50) | VHLRAB9APTGS2ACHE | |
| SCHEMBL22130274 | 0.80 | VHL (0.50) | VHLKDM4EPKMMEN1KMT2A | |
| SCHEMBL28763538 | 0.80 | VHL (0.50) | VHLKDM4EPKMMEN1KMT2A | |
| SCHEMBL26132897 | 0.79 | VHL (0.61) | VHLMKNK1MKNK2ELOCELOB | |
| SCHEMBL679793 | 0.79 | KDM4E (0.53) | VHLKDM4EPKMMEN1KMT2A | |
| SCHEMBL23880997 | 0.78 | VHL (0.60) | VHLKDM4EPKMRAB9AMAPT | |
| SCHEMBL27331301 | 0.78 | HSD17B1 (0.50) | VHL | |
| SCHEMBL24880893 | 0.78 | VHL (0.52) | VHLKDM4EPKMMEN1KMT2A | |
| SCHEMBL23478765 | 0.77 | VHL (0.48) | VHLKDM4EKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| US-12077555-B2 | STAT degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230120381-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230084113-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11485750-B1 | STAT degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| EP-3946360-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020206424-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020206424-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230084113-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | VHL 600/4885ESR1 788/4885ESR2 2700/4885 |
| US-20230120381-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | VHL 600/4885ESR1 788/4885ESR2 2700/4885 |
| US-12077555-B2 | STAT degraders and uses thereof | STAT4, STAT1, STAT3 | VHL 600/4885ESR1 788/4885ESR2 2700/4885 |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | VHL 4/4885ESR1 61/4885ESR2 27/4885 |
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | VHL 600/4885ESR1 788/4885ESR2 2700/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | VHL 600/4885ESR1 788/4885ESR2 2700/4885 |
| US-11485750-B1 | STAT degraders and uses thereof | STAT4, STAT1, STAT3 | VHL 600/4885ESR1 788/4885ESR2 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.